This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. PRME, MAZE, OPT, AXGN, KIDS, TYRA, MLAB, TLRY, CELC, and RXSTShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Prime Medicine (PRME), Maze Therapeutics (MAZE), Opthea (OPT), AxoGen (AXGN), OrthoPediatrics (KIDS), Tyra Biosciences (TYRA), Mesa Laboratories (MLAB), Tilray Brands (TLRY), Celcuity (CELC), and RxSight (RXST). These companies are all part of the "medical" sector. Elicio Therapeutics vs. Its Competitors Prime Medicine Maze Therapeutics Opthea AxoGen OrthoPediatrics Tyra Biosciences Mesa Laboratories Tilray Brands Celcuity RxSight Prime Medicine (NYSE:PRME) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Which has more volatility and risk, PRME or ELTX? Prime Medicine has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Do institutionals & insiders hold more shares of PRME or ELTX? 70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 22.9% of Prime Medicine shares are owned by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, PRME or ELTX? Elicio Therapeutics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M164.88-$198.13M-$1.61-2.93Elicio Therapeutics$2.30M56.21-$51.90M-$6.95-1.16 Is PRME or ELTX more profitable? Elicio Therapeutics' return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Elicio Therapeutics N/A N/A -185.70% Do analysts prefer PRME or ELTX? Prime Medicine currently has a consensus target price of $10.08, suggesting a potential upside of 113.86%. Elicio Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 23.76%. Given Prime Medicine's higher possible upside, research analysts clearly believe Prime Medicine is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Elicio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PRME or ELTX? In the previous week, Prime Medicine had 4 more articles in the media than Elicio Therapeutics. MarketBeat recorded 5 mentions for Prime Medicine and 1 mentions for Elicio Therapeutics. Prime Medicine's average media sentiment score of 0.92 beat Elicio Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Positive Elicio Therapeutics Neutral SummaryPrime Medicine beats Elicio Therapeutics on 11 of the 16 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.28M$66.29M$5.54B$9.12BDividend YieldN/AN/A5.06%4.01%P/E Ratio-2.06N/A28.2919.57Price / Sales56.21N/A374.5380.34Price / CashN/AN/A24.7227.50Price / Book-7.840.958.255.53Net Income-$51.90M-$26.57M$3.19B$252.38M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics0.8037 of 5 stars$8.08-2.3%$10.00+23.8%+76.8%$129.28M$2.30M-2.06N/APRMEPrime Medicine3.9019 of 5 stars$4.10+7.9%$10.08+145.9%-23.8%$538.31M$3.85M-2.00234High Trading VolumeMAZEMaze TherapeuticsN/A$15.06+24.3%$23.50+56.0%N/A$530.82M$167.50M0.00121News CoverageHigh Trading VolumeOPTOpthea0.3835 of 5 stars$3.41+7.2%$1.33-60.9%N/A$524.84M$120K0.008Gap UpAXGNAxoGen2.3226 of 5 stars$11.48+1.1%$24.50+113.4%+43.9%$517.38M$187.34M-76.53450High Trading VolumeKIDSOrthoPediatrics4.2827 of 5 stars$21.68+2.1%$35.83+65.3%-33.2%$515.85M$204.73M-12.39200Positive NewsTYRATyra Biosciences3.1309 of 5 stars$9.91+3.1%$30.83+211.1%-48.2%$510.19MN/A-6.0820MLABMesa Laboratories3.0113 of 5 stars$92.02-1.0%$130.00+41.3%-18.1%$507.03M$240.98M-248.70680Dividend AnnouncementHigh Trading VolumeTLRYTilray Brands1.8838 of 5 stars$0.59+17.3%$1.92+224.7%-69.1%$506.67M$788.94M-0.562,650High Trading VolumeCELCCelcuity2.6209 of 5 stars$13.40+0.4%$28.40+111.9%-23.3%$505.14MN/A-4.4240News CoveragePositive NewsGap UpRXSTRxSight2.231 of 5 stars$12.79+2.9%$37.90+196.3%-83.2%$505.12M$139.93M-19.09220Analyst Downgrade Related Companies and Tools Related Companies PRME Competitors MAZE Competitors OPT Competitors AXGN Competitors KIDS Competitors TYRA Competitors MLAB Competitors TLRY Competitors CELC Competitors RXST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
